tradingkey.logo

Prothena Announces That Novo Nordisk Will Advance Coramitug Into Phase 3 Development

ReutersAug 6, 2025 2:08 PM

- Prothena Corporation PLC PRTA.O:

  • PROTHENA ANNOUNCES THAT NOVO NORDISK WILL ADVANCE CORAMITUG (FORMERLY PRX004) INTO PHASE 3 DEVELOPMENT FOR ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY

  • PROTHENA CORPORATION: UNDER AGREEMENT, CO IS ELIGIBLE TO RECEIVE UP TO $1.2 BILLION DOLLARS UPON ACHIEVEMENT OF CLINICAL DEVELOPMENT & SALES MILESTONES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI